Iter-4360dd15-0001-transcript
第 1 轮执行轨迹
→ call search_memory({"limit":10,"query":"4360dd15 长生不老 immortality 抗衰老 目标"}) → call list_recent({"n":10})
→ call list_tools({})
【tool:search_memory】
{"ok": true, "results": [{"title": "GOAL", "tags": "goal pinned", "modified": "20260424172208000", "preview": "[[目标]]：找到让人类长生不老的方法 Mission ID：`4360dd15` 起始时间：2026-04-25T01:22:08 !! 使用说明 这是 Sisyphus 的北极星。永远围绕这个目标展开。 其它 mission 的 tiddler 仅供参考，不要跟随它们的 NEXT_FOCUS。 如果某一轮出现了更合理的目标升级，写入 idea 类 tiddler，不要直接改这条。"}, {"title": "Iter-0001-transcript", "tags": "iteration transcript", "modified": "20260424171155000", "preview": "!! 第 1 轮执行轨迹
→ call search_memory({\"limit\":8,\"query\":\"NEXT_FOCUS 质数 100 规律 间隔 差值\"}) → call list_recent({\"n\":8}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-0002-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424171244000\", \"preview\": \"!! 第 2 轮执行轨迹 【tool:list_recent】
{"ok": true, "items": [{"title": "GOAL", "modified": "20260424172208000", "tags": "goal pinned"}, {"title": "NEXT_FOCUS-archived-legacy-20260425-012208", "modified": "20260424172208000", "tags": "archive focus"}, {"title": "Iter-0005-reflection", "modified": "20260424171825000", "tags": "iteration reflection"}, {"title": "先压缩成最小状态机再验证", "modified": "20260424171825000", "tags": "lesson state-machine verification prime"}, {"title": "Iter-0005-transcript", "modified": "20260424171817000", "tags": "iteration transcript"}, {"title": "Prime-100 mod6 minimal transition table verified", "modified": "20260424171809000", "tags": "fact knowledge experiment prime method"}, {"title": "Iter-0004-reflection", "modified": "20260424171717000", "tags": "iteration reflection"}, {"title": "先压缩再证伪", "modified": "20260424171717000", "tags": "lesson enumeration verification prime"}, {"title": "Iter-0004-transcript", "modified": "20260424171711000", "tags": "iteration transcript"}, {"title": "Prime-100 gap motif compressed verified", "modified": "20260424171706000", "tags": "fact knowledge experiment prime"}]}
【tool:list_tools】
{"ok": true, "tools": [{"name": "search_memory", "description": "在 TiddlyWiki 长期记忆中按关键字搜索（支持中文空格分隔），返回标题、标签、预览。每轮迭代开始前应先调用以回忆。", "custom": false}, {"name": "read_note", "description": "读取某一条 tiddler 的完整正文。", "custom": false}, {"name": "write_note", "description": "向 TiddlyWiki 写入（或覆盖）一条 tiddler。这是 Sisyphus 的长期记忆入口——每轮至少写一条。建议标签：knowledge, experiment, reflection, plan, idea, fact, question, lesson。TiddlyWiki 标记：!! 小标题，''粗体''，斜体，其它tiddler。", "custom": false}, {"name": "list_recent", "description": "列出最近修改过的 tiddler。", "custom": false}, {"name": "list_by_tag", "description": "按标签列出相关 tiddler。", "custom": false}, {"name": "run_python", "description": "在 workspace/ 下以子进程执行一段 Python 代码，返回 stdout/stderr。用于计算、模拟、验证假设、抓取公开数据（禁止任何破坏性操作）。", "custom": false}, {"name": "read_file", "description": "读取 workspace/ 下的某个文件。", "custom": false}, {"name": "write_file", "description": "向 workspace/ 下写入文件（默认覆盖，append=true 时追加）。", "custom": false}, {"name": "list_files", "description": "列出 workspace/ 下的文件。", "custom": false}, {"name": "web_fetch", "description": "抓取任意公开 URL（GET），返回剥离 HTML 后的纯文本。适合读论文摘要、文档、博客、百科。", "custom": false}, {"name": "web_search", "description": "用 DuckDuckGo 搜索互联网，返回 title/url/snippet 列表。找入口、找链接、调研时用。", "custom": false}, {"name": "wiki_search", "description": "维基百科搜索：返回若干条目的摘要和 URL。lang 默认 en，可传 zh 等。", "custom": false}, {"name": "arxiv_search", "description": "arXiv 论文检索：标题/作者/摘要/链接。理论、数学、物理、CS、bio 类前沿论文的主入口。", "custom": false}, {"name": "pubmed_search", "descriptio
→ call pubmed_search({"limit":5,"query":"senolytic human trial aging biomarkers review"})
→ call pubmed_search({"limit":5,"query":"rapamycin human trial aging biomarkers review"})
→ call pubmed_search({"limit":5,"query":"partial reprogramming aging review human"})
→ call pubmed_search({"limit":5,"query":"NAD booster aging human trial review"})
【tool:pubmed_search】
{"ok": true, "query": "senolytic human trial aging biomarkers review", "results": [{"pmid": "41933553", "title": "Vascular Aging: A Central Driver of Multimorbidity.", "source": "Ageing Res Rev", "pubdate": "2026 Mar 31", "authors": ["Zheng M", "Su W", "Tian L", "Gao W"], "url": "https://pubmed.ncbi.nlm.nih.gov/41933553/"}, {"pmid": "41863810", "title": "Insights on geroscience pre-clinical and clinical trials to promote healthy aging from the Intrinsic Capacity, Frailty and Sarcopenia Research Task Force 2025.", "source": "J Frailty Aging", "pubdate": "2026 Apr", "authors": ["Tagliafico L", "Canevelli M", "Barreto PS", "Cesari M", "Ferrucci L", "Vellas B", "Rolland Y", "ICFSR Task Force"], "url": "https://pubmed.ncbi.nlm.nih.gov/41863810/"}, {"pmid": "41674227", "title": "Sarcopenia and Muscle Aging: Updated Insights into Molecular Mechanisms and Translational Therapeutics.", "source": "Endocrinol Metab (Seoul)", "pubdate": "2026 Feb", "authors": ["Nguyen TT", "Dao T", "Nguyen HT", "Park JH", "Jeong SJ", "Kim S", "Jo Y", "Thieu NTH"], "url": "https://pubmed.ncbi.nlm.nih.gov/41674227/"}, {"pmid": "41471752", "title": "From Elixirs to Geroscience: A Historical and Molecular Perspective on Anti-Aging Medicine.", "source": "Molecules", "pubdate": "2025 Dec 10", "authors": ["Nicoletti GRP", "Mangano K", "Nicoletti F", "Cavalli E"], "url": "https://pubmed.ncbi.nlm.nih.gov/41471752/"}, {"pmid": "41139485", "title": "Deciphering the nexus of aging and pan-cancer: Single-cell sequenc
【tool:pubmed_search】
{"ok": true, "query": "rapamycin human trial aging biomarkers review", "results": [{"pmid": "41962762", "title": "Why dietary interventions fail or succeed in ageing: metabolic resilience as the missing integrative framework.", "source": "Clin Nutr ESPEN", "pubdate": "2026 Apr 8", "authors": ["Murillo-Cancho AF", "Lozano-Paniagua D", "Martín-Latorre MDM", "Ramírez-Santos J", "Nievas-Soriano BJ"], "url": "https://pubmed.ncbi.nlm.nih.gov/41962762/"}, {"pmid": "41096951", "title": "Heterogeneity of Cellular Senescence, Senotyping, and Targeting by Senolytics and Senomorphics in Lung Diseases.", "source": "Int J Mol Sci", "pubdate": "2025 Oct 4", "authors": ["Ozdemir SA", "Faizan MI", "Kaur G", "Shaikh SB", "Ul Islam K", "Rahman I"], "url": "https://pubmed.ncbi.nlm.nih.gov/41096951/"}, {"pmid": "41096907", "title": "Dietary and Pharmacological Modulation of Aging-Related Metabolic Pathways: Molecular Insights, Clinical Evidence, and a Translational Model.", "source": "Int J Mol Sci", "pubdate": "2025 Oct 2", "authors": ["Murillo-Cancho AF", "Lozano-Paniagua D", "Nievas-Soriano BJ"], "url": "https://pubmed.ncbi.nlm.nih.gov/41096907/"}, {"pmid": "41075072", "title": "Targeting the senescence-associated secretory phenotype to modify osteoarthritis in aging.", "source": "Inflammopharmacology", "pubdate": "2025 Nov", "authors": ["Afzal M", "Rekha MM", "Sahoo S", "Pandey SN", "Maji C", "Goyal K", "Ali H", "Singh SK"], "url": "https://pubmed.ncbi.nlm.nih.gov/41075072/"}, {"pmid": "40995
【tool:pubmed_search】
{"ok": true, "query": "partial reprogramming aging review human", "results": [{"pmid": "41655728", "title": "From wrinkles to malignancy: small-molecule-mediated stem cell approaches in skin aging.", "source": "Methods", "pubdate": "2026 Apr", "authors": ["Alkhammash A", "Alotaibi G"], "url": "https://pubmed.ncbi.nlm.nih.gov/41655728/"}, {"pmid": "41597242", "title": "Partial Reprogramming Is Conserved from Insect to Mammal.", "source": "Cells", "pubdate": "2026 Jan 16", "authors": ["Tolwinski NS", "Fong S", "Shankar S", "Gruber J"], "url": "https://pubmed.ncbi.nlm.nih.gov/41597242/"}, {"pmid": "41512832", "title": "Anti-aging strategies and ex vivo organ rejuvenation.", "source": "Cell Stem Cell", "pubdate": "2026 Jan 8", "authors": ["Haoui M", "Reddy P", "Izpisua Belmonte JC"], "url": "https://pubmed.ncbi.nlm.nih.gov/41512832/"}, {"pmid": "41490578", "title": "The epigenetic rejuvenation promise: Partial reprogramming as a therapeutic strategy for aging and disease.", "source": "Ageing Res Rev", "pubdate": "2026 Mar", "authors": ["Li YY", "Tay FR"], "url": "https://pubmed.ncbi.nlm.nih.gov/41490578/"}, {"pmid": "41475652", "title": "Influencing ovarian aging in reproductive medicine: promise, evidence, and unresolved questions.", "source": "Fertil Steril", "pubdate": "2026 Mar", "authors": ["Eubanks AA", "Goldman KN", "Babayev E", "Duncan FE", "Widra E"], "url": "https://pubmed.ncbi.nlm.nih.gov/41475652/"}]}
【tool:pubmed_search】
{"ok": true, "query": "NAD booster aging human trial review", "results": [{"pmid": "41674227", "title": "Sarcopenia and Muscle Aging: Updated Insights into Molecular Mechanisms and Translational Therapeutics.", "source": "Endocrinol Metab (Seoul)", "pubdate": "2026 Feb", "authors": ["Nguyen TT", "Dao T", "Nguyen HT", "Park JH", "Jeong SJ", "Kim S", "Jo Y", "Thieu NTH"], "url": "https://pubmed.ncbi.nlm.nih.gov/41674227/"}, {"pmid": "41471752", "title": "From Elixirs to Geroscience: A Historical and Molecular Perspective on Anti-Aging Medicine.", "source": "Molecules", "pubdate": "2025 Dec 10", "authors": ["Nicoletti GRP", "Mangano K", "Nicoletti F", "Cavalli E"], "url": "https://pubmed.ncbi.nlm.nih.gov/41471752/"}, {"pmid": "41228565", "title": "The Diet-Obesity-Brain Axis: Metabolic, Epigenetic, and DNA-Repair Pathways Linking Eating Patterns to Cognitive Aging, with an AI-Enabled Translational Perspective.", "source": "Nutrients", "pubdate": "2025 Nov 6", "authors": ["Loomba M", "Bansal S", "Singh KK", "Mishra PK", "Ghosh S", "Raghunath M", "Mishra AK", "Sinha JK"], "url": "https://pubmed.ncbi.nlm.nih.gov/41228565/"}, {"pmid": "40926126", "title": "Emerging strategies, applications and challenges of targeting NAD(+) in the clinic.", "source": "Nat Aging", "pubdate": "2025 Sep", "authors": ["Zhang J", "Wang HL", "Lautrup S", "Nilsen HL", "Treebak JT", "Watne LO", "Selbæk G", "Wu LE"], "url": "https://pubmed.ncbi.nlm.nih.gov/40926126/"}, {"pmid": "40014680", "title": "Roles of
→ call web_search({"limit":5,"query":"2025 review geroscience clinical trials aging interventions human evidence senolytic rapamycin NAD partial reprogramming"})
→ call web_search({"limit":5,"query":"site:pubmed.ncbi.nlm.nih.gov geroscience clinical trials healthy aging review 2025"})
【tool:web_search】
{"ok": true, "query": "2025 review geroscience clinical trials aging interventions human evidence senolytic rapamycin NAD partial reprogramming", "results": [{"title": "Insights on geroscience pre-clinical and clinical trials to promote ...", "url": "https://www.sciencedirect.com/science/article/pii/S2260134126000162", "snippet": "Key topics included the use of aging biomarkers in clinical trials , senotherapeutics, metabolism-targeting medications, and therapeutic strategies beyond pharmacological approaches. The discussions highlighted the growing interest in, and accumulating evidence for, geroscience interventions ."}, {"title": "Longevity Treatments in Human Trials (2024-2025)", "url": "https://www.p05.org/longevity-treatments-in-human-trials-2024-2025/", "snippet": "The field of longevity therapeutics has rapidly progressed from animal studies to human clinical trials in recent years. Multiple approaches - from senolytics to gene therapy - are being tested in clinics around the world. Figure 1 illustrates the geographic span of these trials (primarily in the US, with some in Europe,"}, {"title": "Geroscience: A Translational Review. - Semantic Scholar", "url": "https://www.semanticscholar.org/paper/Geroscience:-A-Translational-Review.-Kritchevsky-Cummings/85c001bb8cf6e8452f252749c2d2b7eab87f3cca", "snippet": "Therapies that inhibit aging biology, such as caloric restriction, metformin, senolytics , or rapalogs, may slow the development and progression of disease and fun
【tool:web_search】
{"ok": true, "query": "site:pubmed.ncbi.nlm.nih.gov geroscience clinical trials healthy aging review 2025", "results": [{"title": "Advancing Geroscience Research - A Scoping Review of Regulatory ...", "url": "https://pubmed.ncbi.nlm.nih.gov/40706485/", "snippet": "We did not identify any geroscience specific regulatory frameworks but identified barriers to their development. For biological aging to advance as a therapeutic target, stakeholders must develop comprehensive regulatory guidelines, incentivize research and conduct public education. Global collabora …"}, {"title": "The interface of geroscience with longitudinal health disparities ...", "url": "https://pubmed.ncbi.nlm.nih.gov/41052293/", "snippet": "Abstract Geroscience may be the juggernaut that coalesces the pathways of biologic knowledge to expand our understanding beyond describing differences in rates of aging to feasible interventions for improving quality of life as we age. To accomplish this, geroscience must interdigitate with long-standing immutable factors about health. As early as the 17th century, physicians and early ..."}, {"title": "From biology of ageing to geroscience: where will knowledge ... - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/40251834/", "snippet": "The development of geroscience will enable the identification and validation, with more relevant clinical evidence, of pro-ageing targets to develop anti-ageing therapies and aim for healthy ageing."}, {"title": "Challenges in developin
→ call web_fetch({"max_chars":5000,"url":"https://pubmed.ncbi.nlm.nih.gov/41863810/"})
→ call web_fetch({"max_chars":5000,"url":"https://pubmed.ncbi.nlm.nih.gov/40926126/"})
→ call web_fetch({"max_chars":5000,"url":"https://pubmed.ncbi.nlm.nih.gov/41490578/"})
→ call web_fetch({"max_chars":5000,"url":"https://pubmed.ncbi.nlm.nih.gov/40706485/"})
【tool:web_fetch】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://pubmed.ncbi.nlm.nih.gov/41863810/'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}
【tool:web_fetch】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://pubmed.ncbi.nlm.nih.gov/40926126/'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}
【tool:web_fetch】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://pubmed.ncbi.nlm.nih.gov/41490578/'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}
【tool:web_fetch】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://pubmed.ncbi.nlm.nih.gov/40706485/'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}
→ call web_search({"limit":8,"query":"human trials longevity interventions senolytics rapamycin metformin NAD partial reprogramming review clinical evidence"})
【tool:web_search】
{"ok": true, "query": "human trials longevity interventions senolytics rapamycin metformin NAD partial reprogramming review clinical evidence", "results": [{"title": "Human trials exploring anti-aging medicines: Cell Metabolism", "url": "https://www.cell.com/cell-metabolism/fulltext/S1550-4131(23)00458-8", "snippet": "Here, we summarize the current knowledge on eight promising drugs and natural compounds that have been tested in the clinic: metformin , NAD + precursors, glucagon-like peptide-1 receptor agonists, TORC1 inhibitors, spermidine, senolytics , probiotics, and anti-inflammatories. Multiple clinical trials have commenced to evaluate the efficacy of such agents against age-associated diseases ..."}, {"title": "Rewinding the Clock: Emerging Pharmacological Strategies for Human Anti ...", "url": "https://www.mdpi.com/1422-0067/26/19/9372", "snippet": "We classify these strategies into five broad categories, including senolytics , senomorphics, NAD+ precursors, mTOR inhibitors, and metabolic modifiers, such as metformin , and review the mechanisms by which they act, preclinical evidence for efficacy, and their translational potential to a clinical context."}, {"title": "Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity ...", "url": "https://clinicaltrials.gov/study/NCT04488601", "snippet": "A randomized, double-blind, placebo-controlled trial assessing the effects of low and high doses of intermittent Rapamycin on a weekly schedule. The researchers aim
→ call web_search({"limit":5,"query":"site:clinicaltrials.gov senolytic aging trial clinicaltrials.gov"})
→ call web_search({"limit":5,"query":"site:clinicaltrials.gov rapamycin aging trial clinicaltrials.gov"})
→ call web_search({"limit":5,"query":"site:clinicaltrials.gov NAD precursor aging trial clinicaltrials.gov"})
→ call web_search({"limit":5,"query":"site:clinicaltrials.gov partial reprogramming aging trial clinicaltrials.gov"})
【tool:web_search】
{"ok": true, "query": "site:clinicaltrials.gov senolytic aging trial clinicaltrials.gov", "results": [{"title": "ClinicalTrials.gov", "url": "https://clinicaltrials.gov/study/NCT04685590", "snippet": "Study record managers: refer to the Data Element Definitions if submitting registration or results information."}, {"title": "PDF Targeting Cellular Senescence with Senolytics to Improve Skeletal ...", "url": "https://cdn.clinicaltrials.gov/large-docs/34/NCT04313634/Prot_SAP_000.pdf", "snippet": "1.1 Background The Mayo Clinic Aging Group is at the forefront of discovering, developing, and optimizing therapies to eliminate senescent cells - \" senolytics \". With aging , DNA damage and/or other cellular stressors(1-4) cause proliferating(5,6) and terminally differentiated, non-dividing cells(7-10) to undergo senescence. Senescent cell characteristics include profound chromatin and ..."}, {"title": "PDF Senolytics to Alleviate Mobility Issues and Neurological Impairment in ...", "url": "https://cdn.clinicaltrials.gov/large-docs/85/NCT05422885/Prot_ICF_000.pdf", "snippet": "The accumulation of senescent cells and their products, which are components of the senescence-associated secretory phenotype (SASP), are associated with age-related deficits in cognition and mobility, including Alzheimer's Disease.15 In mice and humans, \" senolytic \" compounds such as the plant-derived flavanols and tyrosine kinase ..."}, {"title": "PDF Senescence, Frailty, and Mesenchymal Stem Cell Fun
【tool:web_search】
{"ok": true, "query": "site:clinicaltrials.gov rapamycin aging trial clinicaltrials.gov", "results": [{"title": "Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity ...", "url": "https://clinicaltrials.gov/study/NCT04488601", "snippet": "Details for study NCT04488601, | ClinicalTrials.gov A randomized, double-blind, placebo-controlled trial assessing the effects of low and high doses of intermittent Rapamycin on a weekly schedule. The researchers aim to establish a long-term safety profile, determine the long-term efficacy of Rapamycin in reducing clinical aging measures, and biochemical and physiological endpoints associated ..."}, {"title": "PDF Clinical Research Protocol - cdn.clinicaltrials.gov", "url": "https://cdn.clinicaltrials.gov/large-docs/52/NCT04049552/Prot_SAP_000.pdf", "snippet": "Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary o Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial . JAMA Dermatology 154(7): 773-780, 2018."}, {"title": "Effect of Rapamycin in Ovarian Aging (Rapamycin) - ClinicalTrials.gov", "url": "https://clinicaltrials.gov/study/NCT05836025?a=4", "snippet": "The investigators are proposing a prospective, randomized, double-blind, placebo-controlled pilot study assessing the ability of low-dose rapamycin to delay ovarian aging in women. Animal studies have shown the potential of rapamycin in slowing or reversing some age-associated pathways."}, {"title": "Study Details | N
【tool:web_search】
{"ok": true, "query": "site:clinicaltrials.gov NAD precursor aging trial clinicaltrials.gov", "results": []}
【tool:web_search】
{"ok": true, "query": "site:clinicaltrials.gov partial reprogramming aging trial clinicaltrials.gov", "results": []}
→ call web_search({"limit":10,"query":"site:clinicaltrials.gov OR site:pubmed.ncbi.nlm.nih.gov OSK partial reprogramming human trial aging"})
→ call web_search({"limit":10,"query":"site:clinicaltrials.gov Yamanaka factors human trial aging"})
→ call web_search({"limit":10,"query":"site:clinicaltrials.gov senolytic human trial aging biomarker"})
→ call web_search({"limit":10,"query":"site:clinicaltrials.gov rapamycin human trial aging biomarker"})
→ call web_search({"limit":10,"query":"site:clinicaltrials.gov NAD precursor human trial aging biomarker"})
【tool:web_search】
{"ok": true, "query": "site:clinicaltrials.gov OR site:pubmed.ncbi.nlm.nih.gov OSK partial reprogramming human trial aging", "results": []}
【tool:web_search】
{"ok": true, "query": "site:clinicaltrials.gov Yamanaka factors human trial aging", "results": []}
【tool:web_search】
{"ok": true, "query": "site:clinicaltrials.gov senolytic human trial aging biomarker", "results": []}
【tool:web_search】
{"ok": true, "query": "site:clinicaltrials.gov rapamycin human trial aging biomarker", "results": []}
【tool:web_search】
{"ok": true, "query": "site:clinicaltrials.gov NAD precursor human trial aging biomarker", "results": []}
→ call run_python({"code":"from textwrap import dedent\n# Build a simple evidence maturity matrix from the collected search results.\nclasses = {\n 'rapamycin / mTOR': {\n 'human_trials': 3, # explicit randomized human trial + review with 19 studies\n 'review_depth': 3,\n 'aging_specificity': 2,\n 'overall_maturity': 3,\n 'key_evidence': [\n 'ClinicalTrials.gov NCT)
【tool:run_python】
{"ok": true, "stdout": "Evidence maturity ranking (human longevity interventions)\n------------------------------------------------------\nrapamycin / mTOR: maturity=3/3, human_trials=3/3, review_depth=3/3, aging_specificity=2/3\n - ClinicalTrials.gov NCT04488601: randomized, double-blind, placebo-controlled trial\n - Lancet Healthy Longev. review: 19 included human studies; improved immune/CV/integumentary parameters\n - Cell Metabolism 2023 review lists TORC1 inhibitors among tested anti-aging agents\n\nsenolytics: maturity=3/3, human_trials=3/3, review_depth=2/3, aging_specificity=2/3\n - ClinicalTrials.gov NCT04313634 protocol: senolytics to improve skeletal muscle / mobility\n - ClinicalTrials.gov NCT05422885 and NCT05276895 indicate active human trial activity\n - 2025 Nature article suggests personalized approach in senolytic trials\n\nNAD+ boosters: maturity=2/3, human_trials=2/3, review_depth=2/3, aging_specificity=1/3\n - Nat Aging 2025 review: \"Emerging strategies, applications and challenges of targeting NAD(+) in the clinic\"\n - Cell Metabolism 2023 review includes NAD+ precursors among clinic-tested compounds\n - Direct aging-specific trial evidence not surfaced in this round\n\npartial reprogramming: maturity=1/3, human_trials=0/3, review_depth=2/3, aging_specificity=3/3\n - Ageing Res Rev 2026 review on partial reprogramming as therapeutic strategy\n - No ClinicalTrials.gov human aging trial surfaced in this round\n - High mechanistic promise, bu
→ call write_note({"tags":["knowledge","fact","experiment",
```